Since 2004, Dr. Scott Rocklage, Ph.D has been a managing partner at 5AM Venture Management, LLC. He initially joined the firm as a venture partner and has over three decades of management in healthcare, leading the approval by the FDA of three new drug applications in the U.S. They are Cubicin, Omniscan and Teslascan. Rocklage has had many clinical trials and has also served as Chairman and CEO of Cubist Parmaceuticals, as well as Nycomed Salutar and has been of assistance of various other R&D positions.
Rocklage has served and does currently serve on many boards. Several of the companies he has been chairman of include Cidara, Kinestral and Rennovia; also included are Epirus and Pulmatrix. Dr. Rocklage has also been Executive Chairman of Ilypsa, Miikana, and Semprus.
Dr. Rocklage had previously said that his business is a life science-based venture capital firm. 5AM Ventures, he noted, was called that because the company is in the formation stages and 5 AM is certainly considered an early part of the day. Rocklage says that in his business, he does not have a typical day. He added that some days are utilized for studying new areas of life science, while other days might be working with the portfolio company’s management team.
So how does Dr. Rocklage really bring his ideas to life? Well, it starts with who he works with: in the business world, he works with executives and entrepreneurs; in the medical world, he works with physicians who work with Rocklage in creating hopeful medicines to treat medical needs that remain unmet.
Rocklage also talks about trends that excite him. One of his most explosive growing trends is targeting specific mutations or genotypes to uniquely treat cancer. “This has already led to extending and saving lives and we will only develop improvements in the near future, which is exciting,” Rocklage said.
Being very well organized is another trait Rockage mentions. It has made him more productive, he says, in regards to calendaring, prioritization and time management.
Bottom line is Rocklage says you cannot be afraid of risk-taking. But he emphasizes that is should be calculated risk. When you rule your own future through entrepreneurship, you do not have the same advantages when working for a Fortune 500. Staying true to what the business knows how to do well and not straying far from strengths is particularly important, he says. Learn more: https://www.crunchbase.com/person/scott-m-rocklage